Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives Undisclosed Milestone from Roche Under RNAi Rx Collaboration

Premium

Alnylam Pharmaceuticals said this week that it has received a milestone payment from Roche related to the initiation of pre-investigational new drug application studies for an RNAi therapeutic covered by a collaboration between the firms.

Financial details about the milestone were not disclosed.

The companies first began working together in 2007. Under that agreement, Roche acquired a non-exclusive license to use Alnylam's fundamental RNAi intellectual property to develop therapeutics in oncology, respiratory diseases, metabolic diseases, and certain liver diseases (see RNAi News, 7/12/2007).

In late 2009, Alnylam announced that the arrangement had advanced to the “RNAi therapeutic-collaboration phase,” under which the companies will jointly develop and commercialize specific, disease-target focused drug candidates based on the gene-silencing technology (see RNAi News, 11/5/2009).

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.